Several SGLT2 inhibitors, such as empagliflozin, dapagliflozin, and canagliflozin, have been found to have cardiovascular benefits in large placebo-controlled clinical trials and are the first oral diabetes drugs that can reduce cardiovascular risk2, 3. The gene discussed is SLC5A2; the disease is diabetes mellitus.